RhemaStem

Executive Summary

RhemaStem is a Milan-based Italian biotechnology company founded in 2016, dedicated to advancing cancer stem cell (CSC) research for colorectal and other solid tumors. The company has developed proprietary platforms for isolating and culturing bona fide CSCs, enabling more physiologically relevant drug discovery. By leveraging deep expertise in normal and cancer stem cell biology, RhemaStem aims to identify novel therapeutic targets and develop effective treatments for difficult-to-treat solid cancers. The company's approach addresses a critical gap in oncology, as CSCs are implicated in tumor relapse, metastasis, and resistance to conventional therapies. As a private, early-stage biotech, RhemaStem's progress is likely in the preclinical phase. Upcoming milestones may include the selection of a lead drug candidate, initiation of IND-enabling studies, or securing strategic partnerships to accelerate development. The company's innovative platform and focused mission position it as a potential player in the cell and gene therapy space, though visibility into its pipeline is limited. With continued funding and successful validation of its technology, RhemaStem could progress toward clinical-stage development within the next few years.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate selection for IND-enabling studies65% success
• H1 2027Strategic partnership or licensing deal50% success
• Q2 2027Series A funding round closure70% success